PLoS ONE (Jan 2013)

Interleukin-27 signaling promotes immunity against endogenously arising murine tumors.

  • Karlo D T Natividad,
  • Simon R Junankar,
  • Norhanani Mohd Redzwan,
  • Radhika Nair,
  • Rushika C Wirasinha,
  • Cecile King,
  • Robert Brink,
  • Alexander Swarbrick,
  • Marcel Batten

DOI
https://doi.org/10.1371/journal.pone.0057469
Journal volume & issue
Vol. 8, no. 3
p. e57469

Abstract

Read online

Interleukin-27 (IL-27) is a pleiotropic cytokine but its immunosuppressive effects predominate during many in vivo immunological challenges. Despite this, evidence from tumor cell line transfer models suggested that IL-27 could promote immune responses in the tumor context. However, the role of IL-27 in immunity against tumors that develop in situ and in tumor immunosurveillance remain undefined. In this study, we demonstrate that tumor development and growth are accelerated in IL-27 receptor α (Il27ra)-deficient mice. Enhanced tumor growth in both carcinogen-induced fibrosarcoma and oncogene-driven mammary carcinoma was associated with decreased interferon-γ production by CD4 and CD8 T cells and increased numbers of regulatory T-cells (Treg). This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent.